longbridge
  • Explore
    Products
    Private Wealth ManagementUS StocksSG StocksHK StocksUS OptionsUS Pre-Market OptionsETFsREITsWarrantsCash Plus
    Tools
    Longbridge SkillLongbridge AILongbridge APIPaper TradingDividend HubLongbridge Pro
  • Café
longbridge

EFUND BIOPHAR ETF

3186

13.2602.50% ( -0.340 )
Delay Closed: Nov 16, 16:08:00
Start trading
OverviewOverviewNewsNewsPostsPostsWikiWikiRatingsRatingsCompositionCompositionDividendsDividends

Overview

EFUND BIOPHAR ETF (3186)

Open
13.250
High
13.280
Low
13.250
Prev. Close
13.600
Volume
23.00K
Turnover
305.17K
Avg Price
13.268
Bid/Ask Ratio
70.00%
Amplitude
0.22%
52wk High
16.950
Volume Ratio
0.32
Turnover Ratio
1.10%
52wk Low
12.710
Dividend YieldTTM
--
DividendTTM
--
NAV
--
NAV Date
--
Disc/Prem Rate
--
Total Issued
2.10M
Assets
27.85M
Min lot size
100
Currency
HKD

News

  • PUBT · Nov 15, 2026 at 10:30 AM

    Hansoh's Aumolertinib Wins EMA Panel Backing for EU Marketing Authorization

  • Tip Ranks · Nov 16, 2026 at 10:40 AM

    Fosun Subsidiary Receives Clinical-Trial Approval for FAP PET Drug

  • PUBT · Nov 16, 2026 at 10:03 AM

    Fosun Pharma Starts Phase II Trial of FXR0906 for Hypertriglyceridemia in China

  • Tip Ranks · Nov 15, 2026 at 10:38 AM

    Hansoh Adds Three Innovative-Medicine Indications to 2026 NRDL

  • CoinLive · Nov 16, 2026 at 10:20 AM

    BeiGene to Invest $19.5 Million in Bravera’s Series A Round

  • StockTitan · Nov 13, 2026 at 07:26 PM

    Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products | ZLAB Stock News

LongbridgeAI
© 2026 Longbridge|Terms of ServicePrivacy Policy